12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Delamanid: Phase IIb data

A double-blind, international Phase IIb trial in 481 patients aged 18-64 with suspected MDR-TB infection showed that twice-daily 100 and 200 mg delamanid in combination with standard background regimen for multidrug-resistant TB each met the primary endpoint of a greater proportion of patients with sputum-culture conversion in liquid broth medium cultured using the Mycobacterial Growth Indicator Tube system at 2 months vs. placebo plus background therapy (45.4% and 41.9%, respectively, vs. 29.6%,...

Read the full 340 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >